|
Donors/patients
|
Immature DCs/mature DCs
|
|---|
|
Healthy donors
|
|
Donor
|
M13
|
N14
|
015
|
|
CD40
|
79/95
|
80/97
|
84/96
|
|
CD80
|
0.1/90
|
1/97
|
18/91
|
|
CD83
|
2/52
|
8/48
|
19/40
|
|
CD86
|
85/98
|
68/98
|
57/97
|
|
IL-10
|
43/46
|
47/214
|
89/112
|
|
IL-12
|
5/400
|
7/29
|
5/182
|
|
Patients with breast cancer
|
|
Patient
|
S219
|
S221
|
S222
|
|
CD40
|
91/93
|
42/86
|
77/86
|
|
CD80
|
3/84
|
4/76
|
4.5/72
|
|
CD83
|
8/17
|
14/66
|
14/72
|
|
CD86
|
87/89
|
25/86
|
68/89
|
|
IL-10
|
46/0
|
57/132
|
30/63
|
|
IL-12
|
bdl/2154
|
bdl/1280
|
bdl/1261
|
- Data are expressed as the percentage of HLA-DR+ cells expressing CD40, CD80, CD83 and CD86, and IL-10 and IL-12 production by dendritic cells (DCs) before and after maturation with cocktail C: Ribomunyl®/Imukin®. Data are individual values from patients S219, S221 and S222. Controls are from three different donors (M13, N14, O15). bdl, below the detection limit; DC, dendritic cell.
